Cardiovascular outcomes and mortality after initiation of canagliflozin: Analyses from the EASEL Study.

In this high cardiovascular risk cohort studied in routine clinical practice, canagliflozin was associated with lower risk of cardiovascular events, cardiovascular death and all-cause mortality with no significant increase in BKLE amputation risk versus non-SGLT2i.